CAJ | 학술논문

目的：观察双歧杆菌三联活菌联合美沙拉嗪治疗轻、中度溃疡性结肠炎的临床疗效。方法选择本院2013年1月~2014年9月门诊及住院的符合轻中度溃疡性结肠炎诊断标准的患者共56例。随机分为对照组及治疗组。对照组26例单独给予美沙拉嗪肠溶片治疗，治疗组30例给予双歧杆菌三联活菌胶囊和美沙拉嗪肠溶片治疗，均连续治疗8周。观察两组治疗后疗效、C 反应蛋白变化及不良反应发生情况。结果治疗组完全缓解15例，好转13例，无效2例，有效率93.3%，对照组完全缓解6例，好转10例，无效10例，有效率61.5%。治疗组临床疗效显著优于对照组，临床症状评分、UC - DAI 及内镜下评分变化较对照组更为显著（ P <0.05）。结论双歧杆菌三联活菌联合美沙拉嗪肠溶片治疗轻、中度溃疡性结肠炎较单独应用美沙拉嗪临床疗效更好，且患者耐受性较好，不良反应少，能降低溃疡性结肠炎的复发率。
목적：관찰쌍기간균삼련활균연합미사랍진치료경、중도궤양성결장염적림상료효。방법선택본원2013년1월~2014년9월문진급주원적부합경중도궤양성결장염진단표준적환자공56례。수궤분위대조조급치료조。대조조26례단독급여미사랍진장용편치료，치료조30례급여쌍기간균삼련활균효낭화미사랍진장용편치료，균련속치료8주。관찰량조치료후료효、C 반응단백변화급불량반응발생정황。결과치료조완전완해15례，호전13례，무효2례，유효솔93.3%，대조조완전완해6례，호전10례，무효10례，유효솔61.5%。치료조림상료효현저우우대조조，림상증상평분、UC - DAI 급내경하평분변화교대조조경위현저（ P <0.05）。결론쌍기간균삼련활균연합미사랍진장용편치료경、중도궤양성결장염교단독응용미사랍진림상료효경호，차환자내수성교호，불량반응소，능강저궤양성결장염적복발솔。
Objective:To observe the clinical effect of Bifidobacterium triple June viable combined with mesalazine on mild - moderate active ulcerative colitis. Methods:To select 56 outpatient and inpatient who accord with the standard of di-agnosis of mild - moderate ulcer colitis from January 2013 to June 2014. Dvided them into treatment group and control group randomly. The 30 cases in treatment group were given the bifidobacterium triple viable and mesalazine enteric coated tablets treatment. The 26 cases in the control group were given the mesalazine enteric coated tablets treatment separately,they both had been treated for 8 weeks. Observed the treatment efficacy of the two groups,c - reactive protein change and adverse re-actions. Results:In the treatment group,15 cases were in remission completely,13 cases were improved,2 cases were in-effective,the efficiency was 93. 3%. In control group ,6 cases were in remission completely,10 cases were improved,10 cases were ineffective,efficiency was 61. 5%. The clinical effect of treatment group was significantly better than the control group,clinical symptoms score,UC - DAI score and endoscopic changed more than control group significantly(P < 0. 05) . Conclusions:The curative effect that Bifidobacterium capsules combined with mesalazine enteric coated tablets in the treat-ment of mild - moderate ulcerative colitis is better than that of single application of mesalazine,and it was well tolerated in patients with less adverse reaction,it could reduce the rate of recurrence of ulcerative colitis.